Articles tagged with Multiple Sclerosis
Researchers at Kessler Foundation found significant improvement in processing speed among individuals with MS after a five-week training intervention. The treatment effect was maintained six months later, with dosage correlating with improved outcomes.
Researchers have demonstrated the efficacy of a six-week interpersonal emotion regulation (IER) intervention for addressing depression often experienced by individuals with multiple sclerosis. IER strategies, such as turning to others for emotional support, significantly reduced depression levels in the treatment group.
A new study finds that multiple sclerosis (MS) affects Black and white adults at similar rates, while being underreported in Hispanic and Asian communities. The study analyzed over 2.6 million adults in Southern California and found MS prevalence per 100,000 people was similarly high for Black and white people, but lower among Hispanic...
A new study published in Neurology found that women with multiple sclerosis (MS) are less likely to have breast cancer detected through routine screenings, despite being twice as likely to have colorectal cancer detected at an early stage. The researchers also found a higher rate of disability among MS patients, which may affect their ...
Researchers at Karolinska Institutet have developed a method to identify the immune cells involved in autoimmune diseases and identified four new target molecules for personalized treatment of multiple sclerosis. This approach could lead to more precise treatments with fewer side effects, potentially benefiting other autoimmune diseases.
Researchers at Universitat Autonoma de Barcelona developed a new treatment that reduces chronic inflammation in multiple sclerosis mice models by administering Maresin-1, a lipid mediator. The substance significantly reduced cytokine levels and protected neurons from demyelination.
A new report estimates the total economic burden of multiple sclerosis (MS) in the United States to be over $85 billion, with direct medical costs reaching $63.3 billion and indirect non-medical costs totaling $22.1 billion. The average excess medical cost per person with MS was found to be $65,612.
Researchers developed EMOPRINT, a five-week behavioral intervention improving facial affect recognition skills in individuals with MS. The study showed significant improvement in facial affect recognition in the MS group compared to placebo controls.
Researchers analyzed genomic profiles of over one million cells from 1,000 people, identifying a link between specific genes and immune cell types in autoimmune diseases. The discovery could lead to tailored treatments and refine clinical trials.
Research published in the Journal of Neurology Neurosurgery & Psychiatry found a strong association between childhood emotional trauma and an increased risk of multiple sclerosis (MS) in women. Women who experienced childhood abuse, particularly sexual abuse, were more likely to develop MS compared to those without a history of abuse.
A new study by University of Alberta immunologist Shokrollah Elahi reveals that killer T cells have low levels of protein CD73, compromising their ability to eliminate HIV-infected cells. Chronic inflammation also plays a role in reducing CD73 expression, leading to potential new treatments for both HIV and multiple sclerosis.
Researchers at Mayo Clinic have developed a new antibody test to diagnose multiple sclerosis (MS), a potentially disabling disease of the brain and spinal cord. The validated test measures kappa immunoglobulin free light chains in cerebrospinal fluid, offering a faster and more cost-effective alternative to existing tests.
A new study published in Multiple Sclerosis and Related Disorders found that individuals with multiple sclerosis experienced increased depression, anxiety, and loneliness during the COVID-19 pandemic. The research suggests that pandemic-related stress may exacerbate mental health issues in MS patients.
A new study led by Kelly Monaghan at West Virginia University suggests that interrupting the immune response may improve multiple sclerosis outcomes. The researchers found that targeting a specific protein called CCL17 can prevent the disease from attacking the central nervous system, leading to milder symptoms and delayed paralysis.
Researchers identified key differences in metabolic processes between brain and spinal cord oligodendrocytes, which could lead to new therapeutic treatments for neurodegenerative diseases. The study also found that targeting a specific cell protein may enhance cholesterol and myelin production.
A new study found that a ketogenic diet significantly improves MS symptoms, including fatigue, depression, and cognitive function. Patients on the keto diet experienced reductions in neurologic disability and enhanced overall quality of life.
A study published in Nature Communications reveals the precise molecular structure of siponimod, a multiple sclerosis drug, and its interactions with S1P receptors. This knowledge may lead to the development of more targeted therapies that reduce side effects.
A new study by University of Bonn researchers found that cow's milk protein casein triggers an autoimmune response in mice, damaging neurons and myelin sheath. This cross-reactivity can occur when the immune system mistakes similar molecules for each other.
New research found that people with multiple sclerosis used online telehealth services more frequently to stay in contact with healthcare providers and were highly satisfied with the outcome. Telehealth appointments nearly doubled the rates of in-person medical care appointments.
Scientists create a hybrid technology called heteroduplex oligonucleotide (HDO) that can safely and effectively silence disease-causing genes in certain immune cells. The HDO delivery method has shown promise in improving symptoms of autoimmune disorders and cancers by regulating the function of T and B lymphocytes.
Researchers found that myelination, even patchy on interneurons, is required for full inhibitory potential. Myelin loss can cause abnormal brain activity and lead to cognitive impairments.
Researchers used identical twins to exclude genetic influences and track immune system changes responsible for triggering multiple sclerosis. The study found that an error in the communication of immune cells leads to greater activation of T cells, causing damage in the central nervous system.
A new study analyzed data from over 27,000 patients with multiple sclerosis to understand the impact of relapses on long-term outcomes. The research found that progression independent of relapse activity can start early in relapsing remitting MS and becomes the dominant driver of disability accumulation as the disease evolves.
A new study on the Symbol Digit Modalities Test (SDMT) has found that group-level scores lack significance on an individual level. The normative study recommends a higher cut-off score for SDMT to accurately assess changes over time and predict disease progression.
Researchers at Johns Hopkins Medicine found that certain stem cells have built-in tracers made of sugars that can track their movement in living tissues. The discovery could streamline and advance restorative research for diseases of the brain.
A recent study analyzed 274 pregnancies of MS patients who discontinued natalizumab before or during pregnancy, finding that stopping the drug can lead to 80% MS relapses within four to seven months. Pregnancy does not provide protection and may even increase risk
A study published in Neuron suggests that oligodendrocytes and immune cells may play a crucial role in multiple sclerosis (MS) development. The research found that genetic mutations near immune genes can activate nearby genes in oligodendrocytes, potentially leading to misfunction and MS risk.
A study by UConn Health and Washington University School of Medicine found that eating more meat correlates with worse MS symptoms, altered gut bacteria, and increased immune cells. The research identified key bacteria and metabolites associated with the disease, providing new insights into its causes.
Researchers have discovered that a bacteria-fighting mechanism in the immune system, NETs, can manipulate beneficial Th17 cells into harmful autoimmune responders. This finding opens doors to developing targeted therapies for multiple sclerosis and other autoimmune conditions.
Researchers at the Josep Carreras Leukaemia Research Institute and the Germans Trias i Pujol Hospital discovered that vitamin D activates the tolerance program of dendritic cells through epigenetic modification. This finding offers new hope for treating autoimmune diseases like multiple sclerosis by optimizing tolerogenic dendritic cells.
Researchers aim to expand an existing spinal cord injury intervention to improve self-efficacy, coping, and well-being in individuals with multiple sclerosis. The study will conduct focus groups and a randomized controlled trial to evaluate the efficacy of the adapted intervention.
A new MRI technique has been developed to detect changes in multiple sclerosis (MS) at an earlier stage. This technique, proton MR spectroscopy with a 7-tesla magnet, can visualize brain changes that appear normal on conventional MRI scans.
A study by Harvard T.H. Chan School of Public Health researchers found a strong association between Epstein-Barr virus infection and multiple sclerosis. The risk of MS increased 32-fold after EBV infection, while serum levels of neurofilament light chain, a biomarker of nerve degeneration, only increased after EBV infection.
A University of Calgary study found that hydroxychloroquine slows worsening of disability in people with primary progressive multiple sclerosis. The experimental trial involved 35 participants and showed promising results for the generic drug.
A new study led by Mount Sinai researchers found that microglia may play a critical role in some cases of brain disease, and provides a comprehensive guide for future studies. The study identified two new genes linked to brain disorders, including Alzheimer's and Parkinson's diseases.
A new neuroimaging technique uses proton MR spectroscopy to detect biochemical changes in the brains of people with multiple sclerosis (MS) early in the course of the disease. The technique shows promise as a valuable tool in the care of MS patients, potentially leading to faster treatment evaluation and improved patient outcomes.
Researchers found high levels of toxic metabolites produced by gut bacteria in MS patients' cerebrospinal fluid and plasma. The discovery suggests a potential therapeutic target for developing new MS therapies.
A pilot study by Kessler Foundation found that methylphenidate improved 'state' mental fatigue in individuals with multiple sclerosis, but had no effect on 'trait' fatigue. The study suggests an important role for dopamine in MS-related mental fatigue.
A pilot study of exercise and cognition in progressive multiple sclerosis found that cardiorespiratory fitness and free-living physical activity were not associated with improved cognitive performance. The study, which analyzed data from 240 individuals with progressive MS, suggests that other mechanisms may be at play.
Research from Queen Mary University of London and Cardiff University found that certain MS treatments can reduce Covid-19 vaccine effectiveness in people with MS. The largest peer-reviewed study on the topic provides high-quality evidence to inform clinicians' guidance on treatment options.
A new evidence review by Oregon Health & Science University researchers found that the expensive multiple sclerosis drug Acthar provides very little clinical benefit compared to less-expensive alternatives. The study screened 41 studies and found weak or no benefit from Acthar against standard medications like corticosteroids.
A new study found that kids, teens and young adults who spend more time outdoors during the summer months have a lower risk of developing multiple sclerosis (MS) as children. The research also suggests that greater time spent outdoors in the first year of life is associated with lower odds of MS.
A new study suggests that sun exposure may reduce the risk of multiple sclerosis in children and young adults by up to 52%. Vitamin D levels are also found to be higher in individuals with increased sun exposure, which may play a role in protecting against autoimmune diseases.
Researchers found improvements in verbal learning and memory and preservation of hippocampal volume in participants with relapsing-remitting multiple sclerosis after 12 weeks of supervised treadmill walking exercise. A targeted pilot randomized controlled trial demonstrated the effectiveness of this intervention for managing cognitive ...
Researchers discover a unique subset of group 3 innate lymphoid cells that circulate in the bloodstream and infiltrate the brain, sparking inflammation in conditions like MS. Countering their activity could be a new therapeutic strategy for such conditions.
A phase 3 clinical trial found that teriflunomide reduced new or enlarged lesions in children with multiple sclerosis, suggesting potential benefits. However, the medication did not delay time to the next clinical relapse.
Researchers found that glatiramer acetate improved cognitive behavior and reduced amyloid plaques in a mouse model of Alzheimer's disease. This study suggests therapies targeting the immune system could be effective in treating the disease.
Researchers at Georgia State University found that vibration training improved both physical and cognitive abilities in adults with MS. Cognitive function improvements included enhanced memory capacity and executive function.
In chronic damage, new cholesterol production determines the efficiency of repair, with nerve cells contributing to replenishing myelin-forming cells. Treatment with a cholesterol-enriched diet enhances oligodendrocyte progenitor cell proliferation.
Scientists at UNIGE discovered that cold therapy can reduce symptoms of multiple sclerosis by shifting energy resources away from the immune system. This approach shows promise for treating autoimmune diseases and could be relevant to other immune-mediated or infectious diseases.
The CMSC Annual Meeting features daily opening lectures with top experts in multiple sclerosis research and care. Key findings include updates on progressive MS, precision neuroimmunology, and the impact of COVID-19 on people with MS.
A new USC study reveals that gaps in income, education, and access to care contribute to poorer outcomes for people of color with multiple sclerosis and other autoimmune diseases. The review shows significant inequities in accessing healthcare, leading to diagnostic delays and underuse of services.
A team of scientists developed a new method to study the effects of reactive electrophiles in the body. By targeting specific proteins with electrophilic compounds, they discovered novel mediators involved in immune-cell apoptosis triggered by Tecfidera, a multiple sclerosis treatment.
Researchers discovered that new mutations in the BRAF gene can lead to gliomas growing back after treatment, suggesting personalized approaches to therapy. The study also explored potential impacts of COVID-19 vaccines on menstruation.
Researchers found that patients with MS receiving aCD20 treatment generated robust CD4 and CD8 T cell responses to the COVID-19 vaccination. The study measured both antibody and T cell responses in 20 patients with MS who were undergoing aCD20 treatment, compared to those in a group of healthy controls.
Researchers at NIH/NINDS built a detailed cellular map of chronic MS lesions, revealing gene activity patterns and interactions that could lead to new therapies. The study identified microglia and C1q as promising targets for progressive MS, potentially offering a way to halt disease progression.
Researchers have identified a molecule called fractalkine that can boost the production of brain cells producing myelin, a key factor in diseases such as multiple sclerosis. The study's findings suggest that fractalkine could be used to treat certain neurodegenerative disorders by restoring lost myelin.
Researchers at TUM have successfully tracked immune cells from the gut and skin into the central nervous system for the first time. This breakthrough could lead to new treatments for multiple sclerosis and other autoimmune diseases.
A new study published in Neurology shows that people with multiple sclerosis (MS) and depression are more likely to die over the next decade than those with MS alone or neither condition. The study also found a higher risk of developing vascular disease, such as heart attack and stroke, among individuals with both MS and depression.
A new study suggests that existing drugs for multiple sclerosis may not be effective due to toxic blood leaks in the brain. Researchers have identified a promising alternative treatment option that could improve myelin repair, even in the presence of these harmful elements.